Cargando…

Genetically identical twins show comparable tau PET load and spatial distribution

Tau accumulation starts during the preclinical phase of Alzheimer’s disease and is closely associated with cognitive decline. For preventive purposes, it is important to identify factors associated with tau accumulation and spread. Studying genetically identical twin-pairs may give insight into gene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coomans, Emma M, Tomassen, Jori, Ossenkoppele, Rik, Golla, Sandeep S V, den Hollander, Marijke, Collij, Lyduine E, Weltings, Emma, van der Landen, Sophie M, Wolters, Emma E, Windhorst, Albert D, Barkhof, Frederik, de Geus, Eco J C, Scheltens, Philip, Visser, Pieter Jelle, van Berckel, Bart N M, den Braber, Anouk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586544/ https://www.ncbi.nlm.nih.gov/pubmed/35022652 http://dx.doi.org/10.1093/brain/awac004

Ejemplares similares

Genetically identical twin-pair difference models support the amyloid cascade hypothesis
por: Coomans, Emma M, et al.
Publicado: (2023)

Performance of a [(18)F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies
por: Coomans, Emma M., et al.
Publicado: (2023)

Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years
por: den Braber, Anouk, et al.
Publicado: (2023)

Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population
por: Padrela, Beatriz E, et al.
Publicado: (2023)

Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals
por: Ingala, Silvia, et al.
Publicado: (2021)

Longitudinal Tau PET Using (18)F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters
por: Visser, Denise, et al.
Publicado: (2023)

Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer’s disease polygenic risk score
por: Tomassen, Jori, et al.
Publicado: (2022)

Abnormal cerebrospinal fluid levels of amyloid and tau are associated with cognitive decline over time in cognitively normal older adults: A monozygotic twin study
por: Tomassen, Jori, et al.
Publicado: (2022)

White matter microstructure disruption in early stage amyloid pathology
por: Collij, Lyduine E., et al.
Publicado: (2021)

In vivo tau pathology is associated with synaptic loss and altered synaptic function
por: Coomans, Emma M., et al.
Publicado: (2021)

Retinal layer thickness in preclinical Alzheimer's disease
por: van de Kreeke, Jacoba A., et al.
Publicado: (2019)

Hippocampal [(18)F]flortaucipir BP(ND) corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
por: Wolters, Emma E, et al.
Publicado: (2019)

Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2022)

Regional [(18)F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease
por: Wolters, Emma E., et al.
Publicado: (2020)

Assessing Amyloid Pathology in Cognitively Normal Subjects Using (18)F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods
por: Collij, Lyduine E., et al.
Publicado: (2019)

Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60–102 Years
por: Legdeur, Nienke, et al.
Publicado: (2019)

Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020)

Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer’s disease
por: Visser, Denise, et al.
Publicado: (2020)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Regional associations of white matter hyperintensities and early cortical amyloid pathology
por: Lorenzini, Luigi, et al.
Publicado: (2022)

Associations between quantitative [(18)F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
por: Timmers, Tessa, et al.
Publicado: (2019)

A novel partial volume correction method for accurate quantification of [(18)F] flortaucipir in the hippocampus
por: Wolters, Emma E., et al.
Publicado: (2018)

Onset of Preclinical Alzheimer Disease in Monozygotic Twins
por: Konijnenberg, Elles, et al.
Publicado: (2021)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals
por: Collij, Lyduine E., et al.
Publicado: (2021)

Altered brain metabolism in frontotemporal dementia and psychiatric disorders: involvement of the anterior cingulate cortex
por: van Engelen, Marie-Paule E., et al.
Publicado: (2023)

Tau protein spreads through functionally connected neurons in Alzheimer’s disease: a combined MEG/PET study
por: Schoonhoven, Deborah N, et al.
Publicado: (2023)

Tau pathology as determinant of changes in atrophy and cerebral blood flow: a multi-modal longitudinal imaging study
por: Visser, Denise, et al.
Publicado: (2023)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

Optical coherence tomography angiography in preclinical Alzheimer’s disease
por: van de Kreeke, Jacoba Alida, et al.
Publicado: (2020)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

Longitudinal retinal layer changes in preclinical Alzheimer’s disease
por: van de Kreeke, Jacoba A., et al.
Publicado: (2020)

Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease
por: den Haan, Jurre, et al.
Publicado: (2019)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Validation and test–retest repeatability performance of parametric methods for [(11)C]UCB-J PET
por: Tuncel, Hayel, et al.
Publicado: (2022)

[(18)F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
por: Wolters, Emma E., et al.
Publicado: (2021)

Parametric methods for [(18)F]flortaucipir PET
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m6gcjsi06u13130518urhegnjc